Katrina L Ellis1,2, Jing Pang1, David Chieng3, Damon A Bell1,3, John R Burnett1,4, Carl J Schultz1,3, Graham S Hillis1,3, Gerald F Watts1,3. 1. School of Medicine, University of Western Australia, Perth, Australia. 2. School of Biomedical Sciences, University of Western Australia, Perth, Australia. 3. Department of Cardiology, Royal Perth Hospital, Perth, Australia. 4. Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, Australia.
Abstract
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) and familial hypercholesterolemia (FH) are inherited lipid disorders. Their frequencies, coexistence, and associations with premature coronary artery disease (CAD) in patients admitted to the coronary care unit (CCU) remain to be defined. HYPOTHESIS: Elevated Lp(a) and FH are commonly encountered among CCU patients and independently associated with increased premature CAD risk. METHODS: Plasma Lp(a) concentrations were measured in consecutive patients admitted to the CCU with an acute coronary syndrome (ACS) or prior history of CAD for 6.5 months. Elevated Lp(a) was defined as concentrations ≥0.5 g/L. Patients with LDL-C ≥ 5 mmol/L exhibited phenotypic FH. Premature CAD was diagnosed in those age < 60 years, and the relationship between this and elevated Lp(a) and FH was determined by logistic regression. RESULTS: 316 patients were screened; 163 (51.6%) had premature CAD. Overall, elevated Lp(a) and FH were identified in 27.0% and 11.6% of patients, respectively. Both disorders were detected in 4.4% of individuals. Elevated Lp(a) (32.0% vs 22.2%; P = 0.019) and FH phenotype (15.5% vs 8.0%; P = 0.052) were more common with premature vs nonpremature CAD. Elevated Lp(a) alone conferred a 1.9-fold, FH alone a 3.2-fold, and the combination a 5.3-fold increased risk of premature CAD (P = 0.005). CONCLUSIONS: Elevated Lp(a) and phenotypic FH were commonly encountered and more frequent with premature CAD. The combination of both disorders is especially associated with increased CAD risk. Patients admitted to the CCU with ACS or previously documented CAD should be routinely screened for elevated Lp(a) and FH.
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) and familial hypercholesterolemia (FH) are inherited lipid disorders. Their frequencies, coexistence, and associations with premature coronary artery disease (CAD) in patients admitted to the coronary care unit (CCU) remain to be defined. HYPOTHESIS: Elevated Lp(a) and FH are commonly encountered among CCU patients and independently associated with increased premature CAD risk. METHODS: Plasma Lp(a) concentrations were measured in consecutive patients admitted to the CCU with an acute coronary syndrome (ACS) or prior history of CAD for 6.5 months. Elevated Lp(a) was defined as concentrations ≥0.5 g/L. Patients with LDL-C ≥ 5 mmol/L exhibited phenotypic FH. Premature CAD was diagnosed in those age < 60 years, and the relationship between this and elevated Lp(a) and FH was determined by logistic regression. RESULTS: 316 patients were screened; 163 (51.6%) had premature CAD. Overall, elevated Lp(a) and FH were identified in 27.0% and 11.6% of patients, respectively. Both disorders were detected in 4.4% of individuals. Elevated Lp(a) (32.0% vs 22.2%; P = 0.019) and FH phenotype (15.5% vs 8.0%; P = 0.052) were more common with premature vs nonpremature CAD. Elevated Lp(a) alone conferred a 1.9-fold, FH alone a 3.2-fold, and the combination a 5.3-fold increased risk of premature CAD (P = 0.005). CONCLUSIONS: Elevated Lp(a) and phenotypic FH were commonly encountered and more frequent with premature CAD. The combination of both disorders is especially associated with increased CAD risk. Patients admitted to the CCU with ACS or previously documented CAD should be routinely screened for elevated Lp(a) and FH.
Authors: Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Leopoldo Pérez de Isla; Rodrigo Alonso; Nelva Mata; Cristina Fernández-Pérez; Ovidio Muñiz; José Luis Díaz-Díaz; Adriana Saltijeral; Francisco Fuentes-Jiménez; Raimundo de Andrés; Daniel Zambón; Mar Piedecausa; José María Cepeda; Marta Mauri; Jesús Galiana; Ángel Brea; Juan Francisco Sanchez Muñoz-Torrero; Teresa Padró; Rosa Argueso; José Pablo Miramontes-González; Lina Badimón; Raúl D Santos; Gerald F Watts; Pedro Mata Journal: Circulation Date: 2017-03-08 Impact factor: 29.690
Authors: A C M Jansen; E S van Aalst-Cohen; M W Tanck; M D Trip; P J Lansberg; A H Liem; H W O Roeters van Lennep; E J G Sijbrands; J J P Kastelein Journal: J Intern Med Date: 2004-12 Impact factor: 8.989
Authors: David Nanchen; Baris Gencer; Olivier Muller; Reto Auer; Soheila Aghlmandi; Dik Heg; Roland Klingenberg; Lorenz Räber; David Carballo; Sebastian Carballo; Christian M Matter; Thomas F Lüscher; Stephan Windecker; François Mach; Nicolas Rodondi Journal: Circulation Date: 2016-07-26 Impact factor: 29.690
Authors: Amit V Khera; Hong-Hee Won; Gina M Peloso; Kim S Lawson; Traci M Bartz; Xuan Deng; Elisabeth M van Leeuwen; Pradeep Natarajan; Connor A Emdin; Alexander G Bick; Alanna C Morrison; Jennifer A Brody; Namrata Gupta; Akihiro Nomura; Thorsten Kessler; Stefano Duga; Joshua C Bis; Cornelia M van Duijn; L Adrienne Cupples; Bruce Psaty; Daniel J Rader; John Danesh; Heribert Schunkert; Ruth McPherson; Martin Farrall; Hugh Watkins; Eric Lander; James G Wilson; Adolfo Correa; Eric Boerwinkle; Piera Angelica Merlini; Diego Ardissino; Danish Saleheen; Stacey Gabriel; Sekar Kathiresan Journal: J Am Coll Cardiol Date: 2016-04-03 Impact factor: 24.094
Authors: Katrina L Ellis; Jing Pang; David Chieng; Damon A Bell; John R Burnett; Carl J Schultz; Graham S Hillis; Gerald F Watts Journal: Clin Cardiol Date: 2018-02-26 Impact factor: 2.882